Survival proportions after treatment initiation with glofitamab and outcomes for clinically relevant patient (pt) subsets. (A) PFS for all pts; (B) OS for all pts; (C) PFS in CAR-T–naive (blue) and CAR-T–exposed (red) pts; and (D) OS in CAR-T–naive (blue) and CAR-T–exposed (red) pts. (E-F) Landmark analysis for PFS (E) and OS (F) in pts depending on response 180 days after start of glofitamab (CR, red; non-CR, blue). (G-H) PFS (G) and OS (H) for pts treated before glofitamab with Benda-containing regimes (red, >6 months; blue, ≤6 months). The P values are obtained using a log-rank test and pts at risk are highlighted below the Kaplan-Meier plot. Benda, bendamustine; exp., exposed; nai., naive.